Literature DB >> 21054462

Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles.

K-A Kim1, W-K Song, K-R Kim, J-Y Park.   

Abstract

BACKGROUND AND
OBJECTIVE: CYP2C19 is a drug-metabolizing enzyme showing various genetic polymorphisms that may cause marked interindividual and interethnic variability in the disposition of its substrates. We assessed CYP2C19 genetic polymorphisms in a Korean population using a newly developed multiplex pyrosequencing method.
METHOD: A multiplex pyrosequencing method to simultaneously detect CYP2C19*2, *3, and *17 alleles was designed. We established the frequency of these CYP2C19 alleles in 271 Korean subjects using the multiplex pyrosequencing method.
RESULTS: The results showed 100% concordance between single and multiplex pyrosequencing methods. We also validated the polymorphisms identified by pyrosequencing with direct sequencing method. The allele frequencies of CYP2C19*2, CYP2C19*3, and CYP2C19*17 were 0·284, 0·101 and 0·015 respectively. These frequencies are similar to that reported for other Asian populations including Japanese and Chinese but different from that of Caucasians and Africans.
CONCLUSIONS: The multiplex pyrosequencing method to detect CYP2C19*2, CYP2C19*3, and CYP2C19*17 concurrently, seems to be a rapid and reliable genotyping method for the detection of important CYP2C19 genetic polymorphisms. Similar to studies conducted on other Asian populations, this study reported that in the Korean population tested, the CYP2C19*2 and CYP2C19*3 alleles were relatively frequently found, whereas the frequency of CYP2C19*17 was very low.
© 2009 The Authors. JCPT © 2009 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21054462     DOI: 10.1111/j.1365-2710.2009.01069.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  21 in total

Review 1.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 2.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

3.  Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

Authors:  Rania Abdelhedi; Nouha Abdelmoula Bouayed; Suad Alfadhli; Leila Abid; Ahmed Rebai; Najla Kharrat
Journal:  J Genet       Date:  2015-12       Impact factor: 1.166

4.  Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.

Authors:  Jeffrey R Bishop; Fedra Najjar; Leah H Rubin; Stephen J Guter; Thomas Owley; Matthew W Mosconi; Suma Jacob; Edwin H Cook
Journal:  Pharmacogenet Genomics       Date:  2015-11       Impact factor: 2.089

5.  Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.

Authors:  Kyoung-Ah Kim; Wan-Geun Song; Hae-Mi Lee; Hyun-Jin Joo; Ji-Young Park
Journal:  Mol Biol Rep       Date:  2014-07-29       Impact factor: 2.316

6.  Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor.

Authors:  Yifan Zhang; Xiaoxue Zhu; Yan Zhan; Xiaojiao Li; Cai Liu; Yunting Zhu; Hong Zhang; Haijing Wei; Yu Xia; Hongbin Sun; Yongqiang Liu; Xiaojuan Lai; Yanchun Gong; Xuefang Liu; Yongguo Li; Yanhua Ding; Dafang Zhong
Journal:  Br J Clin Pharmacol       Date:  2020-06-17       Impact factor: 4.335

7.  Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.

Authors:  Jun-Beom Lee; Kyung-A Lee; Kyung-Yul Lee
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759

Review 8.  Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.

Authors:  Tingyu Wang; Yitian Zhou; Guosheng Cao
Journal:  Eur J Clin Pharmacol       Date:  2021-01-29       Impact factor: 2.953

9.  Genetic Polymorphisms of Cytochrome P450 2C19 in Functional Dyspeptic Patients Treated with Cimetidine.

Authors:  Minhee Kim; Eunhee Kong
Journal:  Korean J Physiol Pharmacol       Date:  2012-10-18       Impact factor: 2.016

10.  SLCO2B1 genetic polymorphisms in a Korean population: pyrosequencing analyses and comprehensive comparison with other populations.

Authors:  Kyoung-Ah Kim; Hyun-Jin Joo; Hae-Mi Lee; Ji-Young Park
Journal:  Mol Biol Rep       Date:  2013-05-11       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.